South Africa Antifungal Drugs Market Size & Outlook
South Africa antifungal drugs market, 2018-2030 (US$M)
Related Markets
South Africa antifungal drugs market highlights
- The South Africa antifungal drugs market generated a revenue of USD 144.7 million in 2023 and is expected to reach USD 209.2 million by 2030.
- The South Africa market is expected to grow at a CAGR of 5.4% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 144.7 million |
| Market revenue in 2030 | USD 209.2 million |
| Growth rate | 5.4% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, South Africa accounted for 0.9% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- Saudi Arabia is the fastest growing regional market in Middle East & Africa and is projected to reach USD 327.2 million by 2030.
Azoles was the largest segment with a revenue share of 47.68% in 2023. Horizon Databook has segmented the South Africa antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
The Medicines and Related Substances Act (as amended), Act No. 101 of 1965 (the Medicines Act), and its Regulations govern the policies for authorization, costing, and reimbursement of pharmaceuticals, biologicals, and medical devices.
The Act and its Regulations are supplemented by Industry Rules and Guidelines. SAHPRA has made these regulations public. In accordance with this Section, the transparent pricing structure comprises a single exit price, which is the only one at which producers may sell prescription drugs and other Scheduled substances to anybody other than the state.
Medical schemes, which entail an undertaking of liability in exchange for a premium or contribution to make provisions for receiving any pertinent healthcare, are also available in South Africa. This responsibility extends to any provider or group of suppliers who provide a relevant health service on behalf of a medical scheme, the medical scheme itself, or in accordance with a contract with a medical scheme.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
South Africa antifungal drugs market size, by drug class, 2018-2030 (US$M)
South Africa Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
